Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4652W HIGH $32.55
Volume
70.40 M
Value Traded
172.46 M
Short % Float
3.21%
Days to Cover
1.0
+8.13%Week
-42.1%1 Month
-80.32%3 Month
-74.09%6 Month
-99.74%5 Year
-99.74%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.57 M
EPS (TTM)
-8.22
P/E Ratio
-
Ent. Value
-4.22 M
Total Shares
1.96 M
Float Shares
1.84 M
Insiders
5.90%
Institutions
5.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
AMIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Autonomix Medical, Inc.
Past FDA Catalysts and PDUFA Decisions
How AMIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Autonomix Medical, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AMIX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pancreatic cancer | 2026-01-09 | consistent pain reduction regardless of disease severityRead More | Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers SymposiumRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Robins David AndrewDirector | Buy | 103,990 110,240 held | $0.00 | 06/18/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in AMIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 7.29 K | 18.69 K |
Ownership Trends
AMIX Short Interest
Shares sold short, counted twice a month.
3.21%
Short % of Float
of tradable shares sold short
59.0K
Shares Sold Short
+119.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
282.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMIX ranks across every disease it competes in
Competitive Position is a premium feature
See how AMIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMIX News
AMIX▲ +5.3%today
Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology
Autonomix Medical has been granted U.S. Patent No. 12,793,841 for its catheter-based sensing technology. This patent enhances the company's intellectual property and supports advanced physiological signal acquisition. The technology aims to improve real-time monitoring and treatment decisions in various clinical applications, including cardiology and pain management.
Read more →AMIXAutonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Autonomix Medical has received a new patent from the Canadian Intellectual Property Office for its catheter-based technologies that enable advanced transvascular access and treatment delivery. This patent reinforces the company's position in nerve-targeted therapies and supports its strategy to enhance neuromodulation technologies. The patent covers innovative methods for real-time procedural validation and adaptive treatment delivery.
Read more →AMIXAutonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
Autonomix Medical, Inc. received favorable FDA feedback regarding its standalone transvascular sensing platform, indicating a Class II regulatory pathway. The company aims for U.S. clearance within 15 months, leveraging substantial equivalence to an already cleared device. This marks a significant milestone in advancing their technology for nerve-targeted treatments.
Read more →AMIXAutonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
Autonomix Medical has been granted a European patent for its technologies assessing neural activity in the eye, enhancing its intellectual property portfolio. This patent supports the company's focus on precision neuromodulation and autonomic nervous system assessment. The CEO emphasized the importance of this expansion for their strategic goals in developing innovative nerve-targeted treatments.
Read more →AMIXAutonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Autonomix Medical has appointed Sandra Cohen Kalter, former Chief Regulatory Counsel at Medtronic, to its Board of Directors. With over four decades of experience in the medical device industry, Kalter will provide strategic guidance as Autonomix develops its nerve-targeted technologies. Her background includes significant roles in regulatory and clinical initiatives at Medtronic, enhancing Autonomix's capabilities.
Read more →AMIXAutonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Autonomix Medical has announced the acceptance of two abstracts for poster presentations at the CIRSE 2026 Annual Congress in Copenhagen. The abstracts, presented by Dr. Robert Schwartz, showcase the company's transvascular technology aimed at improving pain management and neural structure identification. The congress will focus on advancing interventional radiology practices.
Read more →AMIX▼ -11.3%on this news· ran to -33% by day 3
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
Autonomix Medical has received a new U.S. patent for its innovative systems that integrate real-time physiological feedback with targeted therapy delivery. This patent enhances the company's intellectual property portfolio and supports its focus on precision nerve-targeted treatments, particularly for cancer pain management. The technology aims to improve treatment effectiveness through personalized interventions and has applications across various organ systems.
Read more →AMIX▲ +33.9%on this newsshared move
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
Autonomix Medical has entered a warrant inducement agreement to raise approximately $4.9 million through the immediate exercise of outstanding warrants. The transaction involves the issuance of new warrants and is expected to close on or about August 26, 2026. This funding aims to support the company's innovative technologies in nerve-targeted treatments.
Read more →AMIX▼ -17.4%on this news· ran to -30% by day 3
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Autonomix Medical has successfully completed its Good Laboratory Practice (GLP) pre-clinical study, a key milestone for its FDA submission. The study evaluated the safety and performance of its nerve-targeted treatment platform in porcine models, yielding positive results. This achievement is crucial for advancing the company's regulatory strategy and clinical development.
Read more →AMIX▼ -7.5%on this news· ran to -32% by day 3shared move
Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award
Autonomix Medical congratulates its Chief Medical Officer, Dr. Robert Schwartz, for receiving the 2026 Cardiovascular Tech Forum Lifetime Achievement Award. This recognition highlights his influential career and contributions to cardiovascular medicine. The award ceremony will take place on September 18, 2026, in Newport Beach, California. Dr. Schwartz's work has transformed cardiovascular technology and improved patient outcomes.
Read more →AMIX▲ +434.2%on this news
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Autonomix Medical has announced the issuance of U.S. Patent No. 12,433,670, enhancing its precision neuromodulation platform. This patent covers technologies for sensing and targeting nerves associated with tumors and cancer-related pain. The company aims to leverage this technology across various applications, including solid tumors and autonomic nervous system disorders. CEO Brad Hauser emphasized the strategic importance of this patent in strengthening their intellectual property portfolio.
Read more →AMIX▼ -16.6%on this news· ran to +31% by day 3
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Autonomix Medical has announced positive results from a preclinical study demonstrating its neural sensing platform's ability to detect and confirm changes in renal neural activity. The study showed that the platform could identify neural signals associated with nerve activity in the renal artery, supporting the development of physiology-guided renal denervation procedures. The findings suggest a significant advancement in providing real-time physiological feedback during treatment.
Read more →AMIX▼ -12.1%on this news· ran to -31% by day 3shared move
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Autonomix Medical has announced the issuance of U.S. Patent No. 12,471,776, enhancing its intellectual property for autonomic nervous system assessment technologies. This patent covers systems for monitoring physiologic signals, which may improve patient selection and treatment precision. The company aims to revolutionize nerve-targeted therapies, particularly for conditions like pancreatic cancer pain.
Read more →AMIXAutonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Autonomix Medical has been granted a U.S. patent for its innovative platform aimed at diagnosing and treating overactive bladder (OAB), a condition affecting 37 million Americans. The patent enhances the company's neural sensing technology and supports its strategy of organ-specific applications. The catheter-based system allows for precise nerve mapping and targeted therapy delivery, potentially improving treatment outcomes for patients with OAB.
Read more →AMIX▼ -9.7%on this news· ran to -23% by day 3shared move
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical has entered a warrant inducement agreement, allowing an investor to exercise outstanding warrants for approximately $2.6 million. The transaction involves the issuance of new warrants at a reduced exercise price, aimed at advancing the company's innovative nerve-targeted treatment technologies. The closing is expected by July 15, 2026, pending customary conditions.
Read more →AMIX▼ -12.5%on this news· ran to -25% by day 3shared move
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Autonomix Medical has been granted a Canadian patent for its endoscopic sympathectomy systems, enhancing its intellectual property in the nerve-targeted therapy market. This patent supports the company's innovative approach to real-time nerve monitoring and diagnostic evaluation, aiming to improve treatment precision for chronic diseases. The company now holds 112 patents globally, reinforcing its leadership in the denervation market.
Read more →AMIXAutonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Autonomix Medical has announced a standalone neural sensing platform that can detect real-time renal nerve activity changes. This platform aims to enhance renal denervation procedures, potentially improving treatment outcomes for hypertension. The technology is designed for future applications across various nerve-targeted therapies, indicating a strategic expansion into the cardiovascular market.
Read more →AMIXAutonomix Announces Reverse Stock Split
Autonomix Medical, Inc. announced a 1-for-21 reverse stock split effective June 24, 2026. This move will consolidate approximately 11.4 million shares into around 543,000 shares, aimed at improving stock value. The company continues to develop innovative technologies for treating nervous system diseases, particularly focusing on pain management solutions.
Read more →AMIX▼ -6.5%on this news
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
Autonomix Medical has released a new CEO Corner segment featuring CEO Brad Hauser, highlighting the company's growing recognition in the medical field. The segment discusses the acceptance of 13 abstracts at major conferences and the potential impact of their nerve-targeted treatment technology, particularly for pancreatic cancer pain. The company aims to revolutionize treatment through innovative nerve-sensing technology, although it remains investigational.
Read more →AMIXAutonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Autonomix Medical, Inc. showcased its clinical data at the Society of Surgical Oncology Annual Meeting, emphasizing its innovative approach to managing visceral cancer pain. Dr. Toufic Kachaamy discussed the potential impact of their technology, which aims to improve treatment outcomes for pancreatic cancer and other conditions. The presentation's selection for a podium slot underscores its relevance to the surgical oncology community.
Read more →About Autonomix Medical, Inc.
Headquarters21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS, TX, 77380
BIOPHARMAWATCH ELITE
Trade the next AMIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime